Table 1.

Cohort baseline characteristics

Variable	Children <18 (n=93)	Adults >18 (n=45)	P-value
Age	13 (2, 15)	31 (25, 35)	<0.0001
Female	44 (47.3%)	21 (46.7%)	0.94
eGFR (ml/min per 1.73 m2)			<0.0001
40–60	7 (7.5%)	9 (20.0%)
61–75	4 (4.3%)	8 (17.8%)
76–90	6 (6.5%)	14 (31.1%)
91–120	18 (19.4%)	9 (20.0%)
>120	58 (62.4%)	5 (11.1%)
Up/c (g/g)			0.06
1–1.99	18 (19.3%)	15 (33.3%)
2–3.99	21 (22.6%)	15 (33.3%)
4–7.99	24 (25.8%)	7 (15.6%)
8+	30 (32.3%)	8 (17.8%)
Albumin (g/dl)	2.7 (2, 3.5)	3.6 (2.7, 3.8)	0.006
Cholesterol, total (mg/dl)	318 (264, 484)a	261 (230, 368.5)f	0.01
Cholesterol, LDL (mg/dl)	184 (147, 275)b	152 (121, 203)g	0.04
Cholesterol, HDL (mg/dl)	64 (48, 89)a	69.5 (50.5, 93.5)f	0.94
Hemoglobin (anemia levels)			0.91
<11	5 (5.4%)	3 (6.7%)
11–12	5 (5.4%)	3 (6.7%)
≥12	83 (89.3%)	39 (86.7%)
FSGS pathology subtype			0.25
NOS	68 (73.1%)	26 (57.8%)
Perihilar	6 (6.5%)	4 (8.9%)
Cellular	1 (1.1%)	3 (6.7%)
Tip	8 (8.6%)	6 (13.3%)
Collapsing	10 (10.8%)	6 (13.3%)
Duration of FSGS (months)	6.4 (2.9, 12.1)	12.3 (5.4, 19.7)	0.12
Previous steroid exposure (months)	3 (2, 4)c	4 (2, 6)h	0.84
Hypertension	49 (52.7%)	31 (68.9%)	0.07
Premature birth	15 (16.1%)	3 (6.7%)	0.24
Smoking exposure			0.0001
Former smoker	2 (2.1%)	7 (15.6%)
Passive smoker	17 (18.3%)	5 (11.1%)
Current smoker	0 (0.0%)	10 (22.2%)
Thrombotic events	1 (1.1%)	2 (4.4%)h	0.15
Family history
Proteinuria	3 (3.4%)a	5 (12.2%)i	0.14
FSGS	2 (2.3%)d	1 (2.4%)j	0.95
Kidney disease	5 (5.6%)e	7 (15.9%)h	0.03
ESKD	3 (3.4%)e	4 (9.8%)h	0.31

Abbreviations: eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; FSGS, focal segmental glomerulosclerosis; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NOS, not otherwise specified; Up/c, urine protein/creatinine ratio.

Continuous variables are presented as median (interquartile range).

Numbers of subjects:

^a=87;

^b=71;

^c=83;

^d=88;

^e=89;

^f=40;

^g= 35;

^h=44;

ⁱ=41; and

^j=42.